Industry Relations Council
AANN Industry Relations Council (IRC) membership is available to organizations that support the goals and mission of AANN.
The goal of the IRC is to provide a format to build positive relationships and foster dialogue among key industry representatives who have ties to the specialty of neuroscience, to gain greater understanding of mutual areas of interest, and to further programs that benefit patients and their families, neuroscience nurses, and other allied healthcare professionals
Partnership in the IRC is for 1 year. It is a nonvoting partnership with benefits extended to a single corporate-designated representative. The IRC program features tiered participation levels to allow companies of all sizes to enhance their engagement with AANN. Partnership is available at a corporate ($3,000) or executive ($12,500) level.
Benefits of IRC participation include
- 30 minute to an 1-hour meeting between company representatives and a select group of AANN Board members and staff to discuss topics of mutual interest
- a chance to survey the AANN Membership
- an opportunity to send an e-blast to AANN members (sent by AANN on your behalf)
- registration for IRC representatives at the AANN annual meeting
- invitation to the President's Reception with AANN board members
- recognition throughout the year on the AANN website, on signage at the Annual Educational Meeting, and in the program guide, which is distributed to all meeting attendees.
Industry Relations Council Members
AANN proudly recognizes the following IRC corporate partners and thanks them for their support. Please note, AANN does not endorse any company or product.
As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we are a fully integrated pharmaceutical business with discovery, clinical, and marketing capabilities. Our key areas of focus include oncology and neurology (dementia-related diseases and neurodegenerative diseases). To learn more about Eisai Inc., please visit us at www.eisai.com/US and follow us on Twitter and LinkedIn.
Ella the Jellyfish The first Amazon Alexa skill designed for those affected by Lennox-Gastaut Syndrome (LGS). Ella the Jellyfish was created with input from children living with LGS, a rare and severe form of childhood-onset epilepsy, their families and caregivers and is provided free of charge. Featuring capabilities such as interactive play, listening and creative activities, Ella the Jellyfish was designed for easy and seamless daily use on Alexa-enabled devices, including voice assistants, mobile phones and tablets. By simply saying, “Alexa, open Ella the Jellyfish,” families, caregivers and children can instantly and easily interact with Ella and her underwater friends by listening to Ella tell a story, singing a song, listening to a relaxing meditation or playing such games as “Ella Says, Freeze Dance” and “Color Hunt.” https://www.ellathejellyfish.com/
View a Facebook Live event focused on epilepsy during the upcoming American Epilepsy Society (AES) annual meeting.
Hosted on the Jumo Health Facebook Page: http://bit.ly/JumoHealth
Neurelis, Inc. is a privately-held San Diego-based specialty pharmaceutical company organized to license, develop, and commercialize product candidates for epilepsy and the broader central nervous system (CNS) market. Neurelis is leveraging its expertise in the development and commercialization of CNS compounds and strong relationships with leading researchers and clinicians in these markets to advance unique product candidates, such as NRL-1 for the treatment of acute repetitive or cluster seizures, to address significant unmet medical needs. NRL-1 (intranasal diazepam) is a proprietary formulation of diazepam, delivered via a nasal formulation in a spray, being developed for the management of pediatric and adult patients who require intermittent use of diazepam to control bouts of acute repetitive seizure activity, also known as cluster seizures. NRL-1 has been granted Orphan Drug and Fast Track Designations by the FDA. In clinical trials, NRL-1 has demonstrated high bioavailability, low variability from dose to dose, and was well-tolerated - with reliable dosing, regardless of when administered.
January 2020 Update:
Neurelis announces the FDA approval of VALTOCO, the first nasal seizure rescue medication for ages 6 and above – read the Press Release for details.
Patient service program, myNEURELIS™ (1-866-696-3873). For more information on VALTOCO, please visit www.valtoco.com
Neurocrine Biosciences, a San Diego based biopharmaceutical company, is focused on developing treatments for neurological and endocrine related disorders. The company discovered, developed, and marketed INGREZZA® (valbenazine) capsules, the first FDA-approved product for the treatment of adults with tardive dyskinesia, an involuntary movement disorder. Neurocrine's clinical development programs includes opicapone as an adjunctive therapy to levodopa/DOPA decarboxylase inhibitors in Parkinson's disease patients.
Arbor Pharmaceuticals is an Atlanta, GA based specialty pharmaceutical company which currently markets prescription products for the cardiovascular, hospital and pediatric markets.